The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency.
Please note that following on from advice received from the company this appraisal has now been scheduled into the work programme.
We anticipate that the appraisal will begin during late August 2020 when we will write to you about how you can get involved.